Skip to main content
Jonathan Prenner, MD, Ophthalmology, New Brunswick, NJ, Robert Wood Johnson University Hospital

JonathanLPrennerMD

Ophthalmology New Brunswick, NJ

Retinal Disease

Associate Clinical Professor, Rutgers-Robert Wood Johnson Medical School

Dr. Prenner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Prenner's full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System/Scheie Eye Institute
    University of Pennsylvania Health System/Scheie Eye InstituteResidency, Ophthalmology, 1999 - 2002
  • Zucker School of Medicine at Hofstra/Northwell
    Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1998 - 1999
  • Stony Brook University Health Sciences Center School of Medicine
    Stony Brook University Health Sciences Center School of MedicineClass of 1998

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2004 - 2025
  • MI State Medical License
    MI State Medical License 2002 - 2006
  • PA State Medical License
    PA State Medical License 2000 - 2002
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2014
  • Top Doctors: New York Metro Area Castle Connolly, 2014
  • New York Magazine: Top Doctors Castle Connolly, 2013-2014
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • CLINICAL TRIAL DOWNLOAD: Two-Year Brolucizumab Data
    CLINICAL TRIAL DOWNLOAD: Two-Year Brolucizumab DataMarch 1st, 2019
  • The Retina Fellowship Match: How to Rank Programs
    The Retina Fellowship Match: How to Rank ProgramsDecember 3rd, 2018
  • EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Wet AMD and DME
    EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret in Wet AMD and DMEJune 16th, 2023

Professional Memberships

Hospital Affiliations